Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19. Hoffmann M, Schroeder S, Kleine-Weber H, Muller MA, et al. Antimicrob Agents Chemother 2020;64.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hoffmann M, Schroeder S, Kleine-Weber H, Muller MA, et al. Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19. Antimicrob Agents Chemother 2020;64.
PMID: 32312781